Welcome to our dedicated page for Lakefront Biotherapeutics SEC filings (Ticker: GLPGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakefront Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakefront Biotherapeutics's regulatory disclosures and financial reporting.
Galapagos reported that Bank of America Corporation crossed the 5% disclosure threshold in its shares under Belgian transparency rules. The change followed an acquisition of Galapagos voting rights and equivalent financial instruments on February 9, 2026.
As of February 11, 2026, Bank of America and affiliates held 104,522 direct voting rights and 3,415,894 equivalent financial instruments in Galapagos, representing together 5.34% of the company’s 65,897,071 outstanding shares. The notification formalizes Bank of America’s status as a significant shareholder.